← Back to Search

Other

CT-868 for Type 1 Diabetes

Chula Vista, CA
Phase 1
Recruiting
Research Sponsored by Carmot Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial will look into how a new drug affects people with Type 1 Diabetes to regulate their blood sugar.

Who is the study for?
Adults aged 18-65 with Type 1 diabetes, a BMI between 25.0 and 35.0, who have been managing their condition with an insulin pump or multiple daily injections for at least three months are eligible. Those with a history of cancer, significant medical conditions, surgical weight loss treatments, or uncontrolled diabetes cannot participate.
What is being tested?
The trial is testing the effects of CT-868 on blood sugar control in people with Type 1 Diabetes compared to a placebo and Victoza (a known diabetes medication). Participants will be randomly assigned to receive one of these treatments.
What are the potential side effects?
Possible side effects may include reactions at the injection site, low blood sugar levels (hypoglycemia), nausea, vomiting, diarrhea and potential allergic reactions to the medications used.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2014 Phase 4 trial • 368 Patients • NCT02008682
15%
Nausea
11%
Decreased appetite
8%
Diarrhoea
6%
Lipase increased
1%
Diabetic ketoacidosis
1%
Sudden hearing loss
1%
Bronchitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Liraglutide
Sitagliptin

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: CT-868Experimental Treatment1 Intervention
SC injection of CT-868 Intervention
Group II: VictozaActive Control1 Intervention
SC injection of active comparator
Group III: PlaceboPlacebo Group1 Intervention
SC injection of placebo matching CT-868 dose

Find a Location

Closest Location:Carmot Clinical Research Unit 101· Chula Vista, CA

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Carmot Therapeutics, Inc.Lead Sponsor
7 Previous Clinical Trials
1,282 Total Patients Enrolled
Michael ElliottStudy DirectorCarmot Therapeutics, Inc.
5 Previous Clinical Trials
472 Total Patients Enrolled

Media Library

CT-868 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05794581 — Phase 1
Type 1 Diabetes Research Study Groups: Placebo, CT-868, Victoza
Type 1 Diabetes Clinical Trial 2023: CT-868 Highlights & Side Effects. Trial Name: NCT05794581 — Phase 1
CT-868 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05794581 — Phase 1
~9 spots leftby Dec 2025